TeLuRide-005: EIK1001 in Combination With Pembrolizumab and Chemotherapy in Patients With Stage 4 Non-Small Cell Lung Cancer

Condition: Non-Small Cell Lung Cancer

Sponsor: Eikon Therapeutics

Full Title
EIK1001-005: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer

Study Treatment
Toll-Like Receptor 7 and 8 co-agonist, EIK1001 given in combination with chemotherapy and pembrolizumab

Eligibility/Info
- Stage IV squamous or non-squamous non-small cell lung cancer
- No history of systemic therapy in the advanced/metastatic setting
- No actionable mutation

Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.

Locations
Babylon Medical Oncology
Central Park Medical Oncology
Eastchester Cancer Center
Lake Success Medical Oncology
Patchogue Medical Oncology
Port Jefferson Medical Oncology
Port Jefferson Station Medical Oncology
Riverhead Medical Oncology

Go To Trial Homepage